Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102

Drug candidate active against EGFR and KRAS mutant lung cancer cell lines

Fort Collins, CO, June 11, 2020 – Cetya Therapeutics, Inc. today announced issuance of US Patent No. 10,676,504 and Australian Patent No. 2016229324 covering CT-102, Cetya’s proprietary HDAC inhibitor. CT-102 has demonstrated excellent activity in vitro against difficult to treat lung cell lines. As no HDAC inhibitor is yet approved for treatment of any solid tumor, CT-102 has a different mechanism of action to existing therapies and is thus a good candidate to include in combinatorial approaches to treatment of these resistant subtypes of lung cancer. Gene expression analysis has been performed on these cell lines with and without treatment with CT-102 to better understand why CT-102 is showing sub-micromolar single agent activity in these growth inhibition assays. CT-102 was seen to alter the expression of genes in important oncogenic pathways related to Check 1 and Wnt inhibitors.

Find out more in the press release.

Categories: Ecosystem News